Biological Membrane Transporters: Delivery Of An Oligonucleotide Inhibitor Of Vascular Endothelial Growth Factor (VEGF)
Funder
National Health and Medical Research Council
Funding Amount
$99,750.00
Summary
Choroidal neovascularisation, which is the most severe form of Age Related Macular Degeneration, is the major cause of blindness in the developed world. Gene therapy could be a cure for this disease if the problems associated with the delivery of DNA could be addressed. Our project involves a highly novel strategy for gene delivery involving ion pair formation of lipophilic dendrimers (tree-like compounds with positive charges on the surface). We will develop new DNA-dendrimer complexes and test ....Choroidal neovascularisation, which is the most severe form of Age Related Macular Degeneration, is the major cause of blindness in the developed world. Gene therapy could be a cure for this disease if the problems associated with the delivery of DNA could be addressed. Our project involves a highly novel strategy for gene delivery involving ion pair formation of lipophilic dendrimers (tree-like compounds with positive charges on the surface). We will develop new DNA-dendrimer complexes and test them in a well established animal model for neovascularisation. Successful completion of this project might offer a potential therapy for choroidal neovascularisation, with a good chance of entering into human clinical trials.Read moreRead less
Novel System For Non-Invasive Delivery Of Drugs To The Interior Of The Eye
Funder
National Health and Medical Research Council
Funding Amount
$200,213.00
Summary
Age-related macular degeneration (AMD) is the leading cause of visual loss for adults in the developed world. Treatment is now by needle injection into the back of the eye, which is painful for the patient and is costly for the health-care system. Seagull Technology Pty Ltd has developed a non-invasive device for treating the back of the eye without the need for a needle injection. This project will test the new device in animals and then move to a first safety study for human AMD patients.
The Respire_ System: Portable Pulmonary Delivery Platform For Rapid, Flexible And Highly Efficient Treatment Of Elderly, Paediatric And Physically-Compromised Patients With Chronic Respiratory Diseases
Funder
National Health and Medical Research Council
Funding Amount
$599,142.00
Summary
The development of a low-cost miniature drug delivery platform for the treatment of chronic respiratory diseases is proposed. The portable device has already been shown to be significantly more efficient than currently available asthma inhalers. In addition, the device offers the possibility of dose adjustment to account for patient variability, such as age and disease severity, as well as a reduction in patient intervention, thus making it more appropriate for patients unable to self-medicate.
Lipoceramic Technologies: A Solution To Low And Variable Bioavailability Of Poorly Soluble Anti-inflammatory Drugs
Funder
National Health and Medical Research Council
Funding Amount
$200,600.00
Summary
A novel oral drug delivery platform will be developed that improves the absorption of poorly soluble drugs from the GI tract, leads to improved clinical outcomes and has significant commercial value. This development will be based on the combination of formulation, in vitro analysis and in vivo animal model studies. An advanced prototype formulation will be established for celecoxib (a non-steroidal anti-inflamatory drug) that will be suitable for human phase 1 clinical trials.
Despite the acknowledged limitations of ophthalmic medication by means of topical guttae therapy, including toxicity, inefficiency and poor compliance, there has been no success in developing a true alternative suitable for a wide range of conditions. The availability of a simple, safe efficacious means of prolonged topical ophthalmic drug delivery would alter the practice of ophthalmology worldwide, with reduced morbidity, improved compliance and direct and indirect health savings. Poor patient ....Despite the acknowledged limitations of ophthalmic medication by means of topical guttae therapy, including toxicity, inefficiency and poor compliance, there has been no success in developing a true alternative suitable for a wide range of conditions. The availability of a simple, safe efficacious means of prolonged topical ophthalmic drug delivery would alter the practice of ophthalmology worldwide, with reduced morbidity, improved compliance and direct and indirect health savings. Poor patient compliance with topical guttae therapy is increasingly recognised as a source of significant morbidity. The occurrence of such a breakthrough in Australia would result in Australia benefiting from the boost to a medical biomaterial industry based here, with a large export market for a high value-m3 product. During the next phase of research for this project, over 1 year, we aim to do the following: Phase I: Manufacture a range of prototype devices, with variations in sponge and surface composition and evaluate these devices using a Sintech mechanical tester for elasticity and strength and by light and environmental scanning electron microscopy for structure and porosity. The liquid loading capacity will also be measured for each variant. Phase II: Using both hydrophilic and lipophilic models, drug loading and release kinetics will be assessed in vitro in a continuous flow system, with drug concentrations being measured by UV-Vis and HPLC. Drug stability within the devices will also be assessed. Phase III: Having determined the optimum sponge formulation and release kinetics in vitro, a pilot study will be undertaken to assess drug release in an animal model. Loaded devices will be placed within the inferior fornix the rabbits for specified periods from 0.5 to 96 hours, then removed so that drug levels remaining in the device can be assessed. After a 2 week flushing period, the experiments will be repeated but with animals being sacrificed at the end of the wearing period so that device levels in intraocular tissues and fluids, as well as remaining in the devices, can be determined at these times, with appropriate controls (‘blank’ devices and guttae therapy). This study will also fulfil the requirements for new device tolerance testing as specified by Regulatory authorities, as animals will be monitored for signs of irritation and histological studies will allow any evidence of inflammation to be identified. These studies do not allow evaluation of the device in a model diseased eye, nor attempt to establish drug loading levels required for human subjects, as there are differences in drug transport across the ocular surfaces of rabbits and humans, but will allow sufficient proof-of-principle for further development to occur.Read moreRead less
Ocular Implant For The Treatment Of Bacterial Endophthalmitis
Funder
National Health and Medical Research Council
Funding Amount
$483,446.00
Summary
We seek to develop an ocular implant for the treatment of bacterial endophthalmitis. The implant will be a small device that can be administered directly to the affected ocular cavity to release an antibiotic in a controlled manner to clear any infection. The implant will erode and leave no residue. It will be produced from a novel drug-polymer conjugate technology that allows polymer devices that comprise >50% drug to be made.
In Vitro And In Vivo Assessment Of The Funhaler -an Innovative Therapeutic Device For Children
Funder
National Health and Medical Research Council
Funding Amount
$472,750.00
Summary
Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler ....Aerosol therapy is the most effective form of treatment for children with respiratory diseases such as asthma. While optimising aerosol delivery systems has an important role in increasing the efficacy of asthma therapy, ensuring patient compliance is often the most difficult part of the clinician's role, particularly in the paediatric age group. An innovative small volume spacer device (Funhaler) developed by a West Australian company (InfaMed, Ltd) may help overcome this problem. The Funhaler incorporates a spinning toy attached to the outside of the spacer. The toy is activated when the patient breathes through the spacer. The device has been designed to encourage children to co-operate when their asthma therapy is being delivered. The Funhaler is currently in the late development stage. We propose, firstly, to carry out in vitro assessments of drug delivery from the Funhaler compared to the two most widely available small volume spacers: the Aerochamber Plus (Trudell, Canada) and the Breath-A-Tech (Scott-Dibben, Australia). These assessments will be carried out to meet the standards of regulatory bodies worldwide (including the FDA). Secondly, we propose to perform extensive in vivo studie: filter studies to assess drug delivery to the patient; deposition studies to measure drug deposition in the lungs; and a pilot clinical trial to assess the efficacy of the device during medium to long-term use in children aged 2-8 years.Read moreRead less
Spectrometer Module For Surface Enhanced Raman Scattering Spectroscopy In Glucose Analysis
Funder
National Health and Medical Research Council
Funding Amount
$385,151.00
Summary
Scientists have developed a number of incredibly powerful and sophisticated techniques to identify chemicals and measure their concentrations in the laboratory. However, it remains a major challenge to perform these measurements under everyday circumstances. For example, surface-enhanced Raman scattering (SERS) has gained widespread recognition as a technique for trace chemical detection, but it remains confined to a small number of specialist laboratories. For this reason, Dr Paul Stoddart at S ....Scientists have developed a number of incredibly powerful and sophisticated techniques to identify chemicals and measure their concentrations in the laboratory. However, it remains a major challenge to perform these measurements under everyday circumstances. For example, surface-enhanced Raman scattering (SERS) has gained widespread recognition as a technique for trace chemical detection, but it remains confined to a small number of specialist laboratories. For this reason, Dr Paul Stoddart at Swinburne University of Technology recognised a need for more practical SERS probes for field applications. His team has now developed a proprietary SERS probe, based on an optical fibre that is little thicker than a hair. These optical fibres can form the core element of field-portable SERS spectrometers. This work has recently been boosted by the discovery in the United States that SERS can be used to monitor glucose in blood. The development of a continuous glucose monitor has long been a holy grail of sensor research, because of the millions of diabetes sufferers who regularly perform the painful finger prick test. For SERS to provide a practical solution to glucose monitoring, it is recognised that SERS optical fibres are needed for minimally invasive probes. With support from Biopharmica and the Diabetes Australia Research Trust, Dr Stoddart's team has now demonstrated that sensitive SERS probes can be produced in large quantities. The next objective is to develop a prototype low-cost SERS spectrometer for use as part of a continuous glucose monitoring system. This will require the development of a laser source and spectroscopic system that can interface to the SERS probes. It is proposed to use an Australian designed and manufactured laser system based on a low-power narrow-linewidth laser diode. The project plans to bring together Swinburne University, OptoTech and Grey Innovation in order to develop a commercially scaleable and robust device.Read moreRead less
Web-based Multimedia Information Management System For Use In Remote Diagnosis Of Eye Diseases
Funder
National Health and Medical Research Council
Funding Amount
$196,000.00
Summary
Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significa ....Our aim is to develop a web-based multimedia information management system for use in remote diagnosis of eye diseases. The proposed system will provide medical advice and diagnosis, information and distance education for those working in health care as well as the community, computer-aided diagnosis and assistance in the operational and medical decision-making process. Less expensive health care personnel should be able to use the system with little training in remote and rural areas. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices. Significantly, the project should empower remote general doctors and nurses by proper access to expert advice, save many remote patients from unnecessary visits to specialist centres on the one hand and allow more proper diagnosis and intervention on the other. It has the potential for significant reductions in the cost of health care delivery, should strengthening the bond between medical services in remote and city areas, provide training and education of local GPs, nurses, health care workers and optometrists and provide web-based disease management systems will provide instant access to health care information. The outcomes of this project are potentially of great significance to remote and rural communities in Australia and around the world. There will be an enormous impact on current health care practices.Read moreRead less
Development Of A Prototype Production System For Optical Fibre Diagnostic Probes
Funder
National Health and Medical Research Council
Funding Amount
$191,598.00
Summary
Advances in nanotechnology have led to new techniques for the precise fabrication of nanometre scale structures. A recent breakthrough by the applicants now allows high-quality nanostructures to be stamped onto the tip of low-cost optical fibre probes. When coated with silver, these sensitive probes can be used for continuous monitoring of blood glucose in diabetics and in critical care situations. This project aims to develop a prototype manufacturing system for optical fibre glucose probes.